scholarly journals PD-1/PD-L1 Expressions on Treg Cells in Patients with Autoimmune Thyroid Disease

2021 ◽  
Author(s):  
Lin Cui ◽  
Xiaotong Gu ◽  
Haixia Liu ◽  
Hong Zheng
Keyword(s):  
T Cells ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Peripheral Blood ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Treg Cells ◽  
Graves Disease ◽  
Newly Diagnosed ◽  
Autoimmune Thyroid

Abstract Background: Autoimmune thyroid disease(AITD) is a frequent autoimmune disease characterized by lymphocytic infiltration and thyroid autoantibody production caused by autoimmune dysfunction. Recent studies have shown that Treg cells can participate in the pathogenesis of AITD by inhibiting peripheral reactive T cells and thereby inhibiting the autoimmune responses. Programmed cell death-1 (PD-1)/programmed cell death ligand (PD-L1) pathway is a negative costimulatory pathway discovered in recent years, enhancing or blocking this pathway is associated with the immune process of AITD. PD-1/PD-L1 was simultaneously expressed on Treg cells. In this paper, the role of regulatory T cells and PD-1/PD-L1 signaling pathway in AITD was discussed.Methods: We detected the percentage of CD4+CD25+CD127lowT cells, the ratio of PD-1+Treg cells and PD-L1+Treg cells in peripheral blood of twenty patients newly diagnosed with graves disease (GD) and twenty-one patients newly diagnosed with Hashimotos’thyroiditis (HT) patients by flow cytometry, and samples from twenty healthy individuals served as control.Results: The results demonstrated that the proportion of CD4+CD25+CD127lowT cells in peripheral blood of HT patients was lower than that of healthy controls(HCs), the ratio of PD-1+Treg cells of HT patients was higher than that of the HCs and GD patients, the ratio of PD-1+Treg cells of GD patients was higher than that of the HCs, the ratio of PD-L1+Treg cells in Treg cells of HT patients was higher than that of the HCs and GD patients and the ratio of PD-L1+Treg cells of GD patients was higher than that of the HCs. All the above were statistically significant.Conclusions: The treg cells play an obvious role in hashimoto's thyroiditis, but not obvious in Graves' disease.

Activated Naive CD4+Peripheral Blood T Cells in Autoimmune Thyroid Disease

Thyroid ◽  
1995 ◽  
Vol 5 (2) ◽  
pp. 117-123 ◽  
Author(s):  
ALOIS GESSL ◽  
ASTRID WILFING ◽  
HERMINE AGIS ◽  
GEORG STEINER ◽  
SOPHIA CZERNIN ◽  
...  
Keyword(s):  
T Cells ◽  
Peripheral Blood ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Autoimmune Thyroid

scholarly journals The proportion of peripheral blood Tregs among the CD4+ T cells of autoimmune thyroid disease patients: a meta-analysis

2020 ◽  
Vol 67 (3) ◽  
pp. 317-326 ◽  
Author(s):  
Ziyi Chen ◽  
Yue Wang ◽  
Xi Ding ◽  
Meng Zhang ◽  
Mingqian He ◽  
...  
Keyword(s):  
T Cells ◽  
Peripheral Blood ◽  
Thyroid Disease ◽  
Cd4 T Cells ◽  
Autoimmune Thyroid Disease ◽  
Meta Analysis ◽  
Autoimmune Thyroid

Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response

2020 ◽  
Vol 105 (9) ◽  
pp. e3392-e3399 ◽  
Author(s):  
Alina Sovetkina ◽  
Rans Nadir ◽  
Antonio Scalfari ◽  
Francesca Tona ◽  
Kevin Murphy ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Graves Disease ◽  
Autoimmune Thyroid ◽  
Tertiary Referral Center ◽  
T2 Lesions ◽  
Relapsing Remitting ◽  
Edss Score ◽  
Multiple Sclerosis Patients

Abstract Context Alemtuzumab is an anti-CD52 monoclonal antibody used in the treatment of relapsing-remitting multiple sclerosis (MS). Between 20% and 40% of alemtuzumab-treated MS patients develop autoimmune thyroid disease (AITD) as a side effect. Objective The objective of this work is to determine whether MS disease progression following alemtuzumab treatment differs in patients who develop AITD compared to those who do not. Design, Setting, and Patients A retrospective analysis of 126 patients with relapsing-remitting MS receiving alemtuzumab from 2012 to 2017 was conducted at a tertiary referral center. Main Outcome Measures Thyroid status, new relapses, Expanded Disability Status Scale (EDSS) score change, and disability progression following alemtuzumab were evaluated. Results Twenty-six percent (33 out of 126, 25 female, 8 male) of alemtuzumab-treated patients developed AITD, 55% of which was Graves disease. EDSS score following alemtuzumab was reduced in patients who developed AITD compared to those who did not (median [interquartile range]; AITD: –0.25 [–1 to 0.5] vs non-AITD: 0 [1-0]. P = .007]. Multivariable regression analysis confirmed that the development of AITD was independently associated with EDSS score improvement (P = .011). Moreover, AITD patients had higher relapse-free survival following alemtuzumab (P = .023). There was no difference in the number of new focal T2 lesions and contrast-enhancing magnetic resonance imaging lesions developed following alemtuzumab between the 2 groups. Conclusion Graves disease was the most common form of AITD developed by MS patients following alemtuzumab. This study suggests that MS patients who develop AITD may have an improved response to alemtuzumab, as measured by reduced disability and lower relapse rate.

scholarly journals A Case of Thyrotoxicosis due to Simultaneous Occurrence of Subacute Thyroiditis and Graves’ Disease

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Kazunori Kageyama ◽  
Noriko Kinoshita ◽  
Makoto Daimon
Keyword(s):  
Thyroid Hormones ◽  
Thyroid Disease ◽  
Rare Case ◽  
Autoimmune Thyroid Disease ◽  
Subacute Thyroiditis ◽  
Simultaneous Occurrence ◽  
Graves Disease ◽  
Inflammatory Disorder ◽  
Autoimmune Thyroid ◽  
Prompt Diagnosis

Subacute thyroiditis is an inflammatory disorder of the thyroid. Graves’ disease is an autoimmune thyroid disease in which thyroid hormones are overproduced. Here we present a rare case of thyrotoxicosis due to the simultaneous occurrence of both diseases. Prompt diagnosis and therapy are required to prevent complications in patients with thyrotoxicosis.

scholarly journals Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma

Cancers ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 450 ◽  
Author(s):  
Saeed Daneshmandi ◽  
Barbara Wegiel ◽  
Pankaj Seth
Keyword(s):  
T Cells ◽  
Cell Death ◽  
Lactate Dehydrogenase ◽  
Programmed Cell Death ◽  
Immune Cell ◽  
Cytotoxic T Cells ◽  
Treg Cells ◽  
Interferon Γ ◽  
Mitochondrial Activity ◽  
Small Subset

Immunotherapy is a curable treatment for certain cancers, but it is still only effective in a small subset of patients. We have recently reported that programmed cell death protein-1 (PD-1) ligand (PD-L1) expression is regulated by lactate present at high levels in the tumor microenvironment (TME). We hypothesized that the efficacy of anti-PD-1 treatment can be improved by blocking the lactate-generating enzyme, lactate dehydrogenase-A (LDH-A). Anti-PD-1 treatment of mice harboring LDH-A deficient B16-F10 melanoma tumors led to an increase in anti-tumor immune responses compared to mice implanted with tumors expressing LDH-A. Specifically, we observed heightened infiltration of natural killer (NK) cells and CD8+ cytotoxic T cells in the LDH-A deficient tumors. These infiltrated cytotoxic cells had an elevated production of interferon-γ (IFN-γ) and granzyme B. Mechanistically, CD8+ T cells isolated from the TME of LDH-A deficient B16-F10 melanoma tumors and treated with anti-PD-1 showed enhanced mitochondrial activity and increased reactive oxygen species (ROS) levels. Moreover, infiltration of T regulatory (Treg) cells was diminished in LDH-A deficient tumors treated with anti-PD-1. These altered immune cell profiles were clinically relevant as they were accompanied by significantly reduced tumor growth. Our study suggests that blocking LDH-A in the tumor might improve the efficacy of anti-PD-1 therapy.

Activation and Suppression of T Cells in Response to Thyroid and Fat Cell Membranes in Patients with Autoimmune Thyroid Disease

1985 ◽  
Vol 69 (s12) ◽  
pp. 23P-23P
Author(s):  
C.J. O'Brien ◽  
S. Vento ◽  
T. Cundy ◽  
C. MacSorley ◽  
A.L.W.F. Eddleston ◽  
...  
Keyword(s):  
T Cells ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Cell Membranes ◽  
Fat Cell ◽  
Autoimmune Thyroid

Evidence of Limited Variability of Antigen Receptors on Intrathyroidal T Cells in Autoimmune Thyroid Disease

1991 ◽  
Vol 325 (4) ◽  
pp. 238-244 ◽  
Author(s):  
Terry F. Davies ◽  
Andreas Martin ◽  
Erlinda S. Concepcion ◽  
Peter Graves ◽  
Lydia Cohen ◽  
...  
Keyword(s):  
T Cells ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Antigen Receptors ◽  
Autoimmune Thyroid

scholarly journals MANAGEMENT OF ENDOCRINE DISEASE: Predictive scores in autoimmune thyroid disease: are they useful?

2019 ◽  
Vol 181 (3) ◽  
pp. R119-R131 ◽  
Author(s):  
Grigoris Effraimidis
Keyword(s):  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Prediction Models ◽  
Prediction Score ◽  
Predictive Score ◽  
Antithyroid Drugs ◽  
Newly Diagnosed ◽  
Endocrine Disease ◽  
Autoimmune Thyroid ◽  
Graves Orbitopathy

Prediction models are of a great assistance for predicting the development of a disease, detecting or screening undiagnosed patients, predicting the effectiveness of a treatment and helping toward better decision-making. Recently, three predictive scores in the field of autoimmune thyroid disease (AITD) have been introduced: The Thyroid Hormones Event Amsterdam (THEA) score: a predictive score of the development of overt AITD, the Graves’ Events After Therapy (GREAT) score: a prediction score for the risk of recurrence after antithyroid drugs withdrawal and the Prediction Graves’ Orbitopathy (PREDIGO) score: a prediction score for the development of Graves’ orbitopathy in newly diagnosed patients with Graves’ hyperthyroidism. Their construction, clinical applicability, the possible preventative measurements which can be taken to diminish the risks and the potential future developments which can improve the accuracy of the predictive scores are discussed in this review.

Sign in / Sign up

Export Citation Format

Share Document